Multiplex Biomarker Assay for Early Pancreatic Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting pancreatic cancer are inadequate, leading to late-stage diagnoses and poor prognosis, necessitating the development of effective early detection techniques.
Innovation Solution
The use of diagnostic compositions and methods that measure levels of CA19-9 polysaccharide and specific polynucleotides or polypeptides (OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP) to detect pancreatic cancer, differentiate it from benign conditions, and select appropriate treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current detection methods are used, then diagnostic simplicity is maintained, but detection precision and early diagnosis capability deteriorate
Solution Approach 1:
The patent combines multiple biomarker detection capabilities into a single integrated diagnostic assay. The composition simultaneously detects CA19-9 polysaccharide and multiple polypeptide markers (OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, LGALS3BP) in one test, merging what would traditionally require separate assays into a unified platform that achieves high detection precision without proportionally increasing operational complexity
Solution Approach 2:
The diagnostic composition serves multiple functions: it detects pancreatic cancer presence, distinguishes malignant from benign conditions, and provides prognostic information. By creating a multi-functional assay that addresses several diagnostic needs simultaneously, the invention improves measurement precision across multiple parameters while avoiding the need for multiple separate diagnostic procedures
2Reliability
If single-marker detection is used, then assay simplicity is maintained, but detection reliability and accuracy deteriorate
Solution Approach 1:
The patent merges detection of multiple biomarkers (CA19-9 polysaccharide and eight different polypeptides) into a single comprehensive assay. This combination approach increases detection reliability by cross-validating signals across multiple markers, ensuring that pancreatic cancer diagnosis is supported by concordant evidence from several independent biomarkers rather than relying on a single marker's signal
Solution Approach 2:
The diagnostic composition functions as a composite assay system integrating multiple detection specificities. By combining antibodies and reagents that recognize different biomarkers into one unified composition, the system achieves enhanced reliability through multi-parameter detection while managing complexity through integrated assay design
3Reliability
If early detection methods are developed, then patient prognosis is improved, but detection complexity increases
Solution Approach 1:
The diagnostic composition provides universal applicability across different stages and types of pancreatic cancer detection. It can identify early-stage disease through sensitive detection of multiple biomarkers, distinguish between malignant and benign conditions, and provide prognostic stratification. This multi-functional capability improves patient prognosis by enabling earlier and more accurate diagnosis while managing complexity through a single integrated test rather than multiple specialized assays
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances early detection and characterization of pancreatic cancer, improving patient prognosis by identifying increased levels of these markers, particularly through multiplexed bead-based immunoassays in serum samples.
Implementation Method 1
measuring in a sample from the subject levels of markers comprising or consisting of a CA19-9 polysaccharide, a HSP27 polynucleotide or polypeptide, and a MIA polynucleotide or polypeptide, using a multiplexed bead based immunoassay
Data Source
AI summary
Provided herein are methods of detecting pancreatic cancer in a subject, the method comprising measuring in a sample from the subject a level of CA19-9 polysaccharide relative to a reference, and a level of a polynucleotide or polypeptide of at least one marker selected from the group consisting of: OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP relative to a reference, wherein an increased level of the CA19-9 polysaccharide relative to a reference and an increased level of the polynucleotide or polypeptide relative to a reference indicates presence of pancreatic cancer in the subject.